Showing results (421-430 of 824) with videos related to

Sort By:
Pageof 83
Oncoimmunology|May 6, 2015
Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cellsJooeun Bae, Mehmet Samur, Aditya Munshi, et al.
Expert Opinion on Emerging Drugs|October 30, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial dataClifton C Mo, Yuxin Liu, Omar Nadeem, et al.
Expert Review of Hematology|July 26, 2024
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomideYuxin Liu, Clifton C Mo, Monique A Hartley-Brown, et al.
Haematologica|May 28, 2026
A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myelomaOmar Nadeem, Robert A Redd, Peter M Barth, et al.
Leukemia|July 21, 2018
A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivityJiye Liu, Tianyu Song, Wenrong Zhou, et al.
Leukemia|June 12, 2019
The effects of MicroRNA deregulation on pre-RNA processing network in multiple myelomaSophia Adamia, Ivane Abiatari, Samir B Amin, et al.
BMC Genomics|October 18, 2014
Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone diseasePaul Dowling, Catriona Hayes, Kay Reen Ting, et al.
Frontiers in Oncology|February 25, 2022
Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted TreatmentClaudio Cerchione, Saad Z Usmani, A Keith Stewart, et al.
Cancer|February 14, 2006
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trialPaul G Richardson, Bart Barlogie, James Berenson, et al.
The Journal of Chemical Physics|October 5, 2013
Phase transitions in human IgG solutionsYing Wang, Aleksey Lomakin, Ramil F Latypov, et al.
Pageof 83